Notice: Function _load_textdomain_just_in_time was called incorrectly. Translation loading for the wordpress-seo domain was triggered too early. This is usually an indicator for some code in the plugin or theme running too early. Translations should be loaded at the init action or later. Please see Debugging in WordPress for more information. (This message was added in version 6.7.0.) in /var/www/html/wp-includes/functions.php on line 6260 Sandoz to Acquire U.S. Biosimilar CIMERLI | Contract Pharma

What are you searching for?

Sign in
Breaking News

Sandoz to Acquire U.S. Biosimilar CIMERLI

Inclusive of biologics license application, product inventory, ophthalmology sales and field reimbursement talent.

Author Image

By: Kristin Brooks

Managing Editor, Contract Pharma

Sandoz, a generic and biosimilar medicines company, has signed an agreement to acquire the U.S. biosimilar ranibizumab CIMERLI (ranibizumab-eqrn) from Coherus BioSciences, Inc. for $170 million up front. This is inclusive of a biologics license application, product inventory, ophthalmology sales and field reimbursement talent, as well as access to proprietary commercial software.
 
Keren Haruvi, President Sandoz North America, said, “I am pleased that we can add another high-value product to the growing Sandoz biosimilar portfolio, further strengthening our existing ophthalmology franchise. The addition of CIMERLI reinforces our commitment to biosimilars and represents a huge step towards our goal of pioneering patient access to more affordable and much-needed medicines in the U.S.”
 
The agreement to acquire the CIMERLI business from Coherus expands Sandoz’s ophthalmic platform that would support future product launches.

Add us as a preferred source on Google

Get the latest Contract Pharma news, insights and analysis in your Google Search and AI experiences.

Add Contract Pharma as a preferred source on Google (opens in a new tab)

Keep Up With Our Content. Subscribe To Contract Pharma Newsletters

Topics